Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupixent in Adults With Refractory Post-Burn Pruritus
NCT06226610Phase 2Recruiting
- Sponsor
- Akron Children's Hospital
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pruritus comparing ARM 1 - Dupixent with ARM 2 - Placebo (2 arms). Primary endpoint: Itch Severity Scale at 12 weeks. Started Nov 2024; status: recruiting.
02
Drugs
03
Conditions
pruritus
Beyond the preview
Go deeper on NCT06226610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226610.